In patients with pancreatic adenocarcinoma, blockade of CCR2 prevented the accumulation of TAM in tumour sites but led to a compensatory CXCR2+ TANs influx, which possibly limited the intended treatment efficacy.157. This evidence concerns the gene CXCR2 and neoplasm.